Altamira Therapeutics
Altamira Therapeutics
CYTO
NASDAQ
0.10
USD
0.00%
About
Altamira Therapeutics Ltd. is a Bermuda-based company engaged in developing ribonucleic acid (RNA)-based therapeutics for extrahepatic targets (OligoPhore/SemaPhore delivery platforms). The Company has two flagship short interfering (siRNA) programs in preclinical development beyond in vivo proof of concept: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis.
The delivery platform is also suited for messenger RNA (mRNA) and other types of RNA therapeutics and is focused to be leveraged via out-licensing to pharma or biotech companies. The therapeutic objective for AM-401 is to slow down KRAS driven tumor cell growth and proliferation or to stop it altogether by delivering siRNA specifically inside tumor cells for gene knock down.
AM-411 is a polyplex nanoparticle delivering siRNA to inflamed tissues to target the NF-kB signaling pathway, a critical regulator of immune and inflammatory responses. Like AM-401, the drug product is based on its OligoPhore technology..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 92.8K |
| Three Month Average Volume | 9.5M |
| High Low | |
| Fifty-Two Week High | 17.2 USD |
| Fifty-Two Week Low | 0.79 USD |
| Fifty-Two Week High Date | 30 Nov 2023 |
| Fifty-Two Week Low Date | 05 Aug 2024 |
| Price and Volume | |
| Current Price | 0.8921 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -21.81% |
| Thirteen Week Relative Price Change | -45.52% |
| Twenty-Six Week Relative Price Change | -66.61% |
| Fifty-Two Week Relative Price Change | -90.11% |
| Year-to-Date Relative Price Change | -78.35% |
| Price Change | |
| One Day Price Change | -2.49% |
| Thirteen Week Price Change | -41.69% |
| Twenty-Six Week Price Change | -63.29% |
| Five Day Price Change | -6.62% |
| Fifty-Two Week Price Change | -87.61% |
| Year-to-Date Price Change | -74.36% |
| Month-to-Date Price Change | -18.16% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -0.07437 USD |
| Book Value Per Share (Most Recent Quarter) | -0.07437 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.07437 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.07437 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.25544 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.12598 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.22062 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.417 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -27.48394 USD |
| Normalized (Last Fiscal Year) | -1.38886 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.417 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -27.48394 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.417 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -27.48394 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.39049 USD |
| Cash Per Share (Most Recent Quarter) | 0.39049 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -7.47629 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.71973 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -29,651 |
| Cash Flow Revenue (Trailing Twelve Months) | -326 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,187.27% |
| Pretax Margin (Last Fiscal Year) | -1,187.27% |
| Pretax Margin (5 Year) | -26,794.36% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -8.40% |
| Gross Margin (Trailing Twelve Months) | -8.39% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -1,094.41% |
| Operating Margin (Trailing Twelve Months) | -1,094.41% |
| Operating Margin (5 Year) | -24,751.30% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -1,124.78% |
| Net Profit Margin (Trailing Twelve Months) | -1,124.78% |
| Net Profit Margin (5 Year) | -26,516.34% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -45.59% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -57.93% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 101.24% |
| EPS Change (Trailing Twelve Months) | 94.33% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -554,810 |
| Net Debt (Last Fiscal Year) | -554,810 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11 |
| Price to Sales (Trailing Twelve Months) | 11 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 2 |
| Quick Ratio (Most Recent Quarter) | 2 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -607,350 |
| Free Cash Flow (Trailing Twelve Months) | -607,350 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -12 |
| Net Interest Coverage (Trailing Twelve Months) | -12 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -45.74% |
| Return on Assets (Trailing Twelve Months) | -45.74% |
| Return on Assets (5 Year) | -68.57% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -143.15% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -117.99% |